TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) — Stella
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(22 sites)
United States
Wichita Urology Group PA, Wichita, Kansas
Duke University Medical Center, Durham, North Carolina
Carolina Urologic Research Center, Myrtle Beach, South Carolina
Huntsman Cancer Institute, Salt Lake City, Utah
Australia
Novartis Investigative Site, Camperdown, New South Wales
Novartis Investigative Site, Wollongong, New South Wales
China
Novartis Investigative Site, Guangzhou
France
Novartis Investigative Site, Créteil
Novartis Investigative Site, Lille
Novartis Investigative Site, Nantes
Germany
Novartis Investigative Site, Essen
Hong Kong
Novartis Investigative Site, Hong Kong
Hungary
Novartis Investigative Site, Budapest
Novartis Investigative Site, Szeged
Italy
Novartis Investigative Site, Rozzano, MI
Novartis Investigative Site, Verona, VR
South Korea
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Spain
Novartis Investigative Site, Majadahonda, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Turkey (Türkiye)
Novartis Investigative Site, Ankara, Sihhiye-Altindag